Aber 2017 |
Ineligible study design |
Akhtar 2021a |
Ineligible population |
Akhtar 2021b |
Ineligible population |
Akiyama 2018 |
Ineligible study design |
Baker 2012 |
Ineligible setting |
Bonilla‐Escobar 2018 |
Ineligible population (clinical patients) |
Bryant 2022 |
Ineligible population (clinical patients) |
Chen 2014 |
Ineligible population (clinical patients) |
Cuijpers 2022 |
Ineligible population (clinical patients) |
De Graaff 2022 |
Ineligible setting |
DRKS00023505 |
Ineligible population (clinical patients) |
El‐Khani 2021 |
Ineligible population (clinical patients) |
Farhood 2014 |
Ineligible study design |
Fine 2021 |
Ineligible population (clinical patients) |
Green 2019 |
Ineligible intervention |
Greene 2021 |
Ineligible population (clinical patients) |
Haar 2021 |
Ineligible setting |
Hasha 2022 |
Ineligible setting |
Hirani 2018 |
Ineligible setting |
Jordans 2021 |
Ineligible population (clinical patients) |
Karam 2008 |
Ineligible study design |
Karibwende 2023 |
Ineligible population (clinical patients) |
Kim 2023 |
Ineligible comparison |
Koch 2020 |
Ineligible setting |
Koebach 2021 |
Ineligible population (clinical patients) |
Lange‐Nielsen 2012 |
Ineligible population |
Lenglet 2018 |
Ineligible population (clinical patients) |
Li 2022 |
Ineligible setting |
Miller‐Graff 2022 |
Ineligible comparison |
Morris 2012 |
Ineligible study design |
Murray 2015 |
Ineligible population (clinical patients) |
NCT03359486 |
Ineligible population (clinical patients) |
Neville 2022 |
Ineligible study design |
Newnham 2015 |
Ineligible study design |
NTR6842 |
Ineligible setting |
Orengo‐Aguayo 2022 |
Ineligible design |
Ramaiya 2022 |
Ineligible design |
Sangraula 2020 |
Ineligible population (clinical patients) |
Sangraula 2023 |
Ineligible population (clinical patients) |
Tam 2020 |
Ineligible setting |
Tol 2008 |
Ineligible population (clinical patients) |
Tol 2014 |
Ineligible population (clinical patients) |
Tol 2020 |
Ineligible population (clinical patients) |
Weiss 2015 |
Ineligible population (clinical patients) |
Welton‐Mitchell 2018 |
Ineligible study design |